Evidence map›Paper›PMID 39669621›Full record

ArticleGenetics in medicine open2024

Health-related quality of life in patients with diverse rare diseases: An online survey.

Anoushka Rao, Megan Yabumoto, Eliana Ward-Lev, Emily G Miller, Hetanshi Naik, Meghan C Halley

Abstract read
In one paragraph

Article in Genetics in medicine open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anoushka RaoCenter for Biomedical Ethics, Stanford University School of Medicine, Stanford, CA.
Megan YabumotoCenter for Biomedical Ethics, Stanford University School of Medicine, Stanford, CA.
Eliana Ward-LevCenter for Biomedical Ethics, Stanford University School of Medicine, Stanford, CA.
Emily G MillerCenter for Biomedical Ethics, Stanford University School of Medicine, Stanford, CA.
Hetanshi NaikDepartment of Genetics, Stanford University School of Medicine, Stanford, CA.
Meghan C HalleyCenter for Biomedical Ethics, Stanford University School of Medicine, Stanford, CA.

Funding

What comes next? Engaging stakeholders in governance of participant data and relationships during the sunset of large genomic medicine research initiativesU01HG010218 · NHGRI · STANFORD UNIVERSITY · PI ASHLEY, EUAN A, BERNSTEIN, JONATHAN ADAM · 2018 to 2022
$6.3M
Surfacing values in the economic evaluation of genomic sequencing for diagnosis of children with rare diseasesK01HG011341 · NHGRI · STANFORD UNIVERSITY · PI HALLEY, MEGHAN · 2021 to 2025
$868k
NHGRI NIH HHS K01 HG011341NHGRI NIH HHS U01 HG010218
6 · The paper itself

Abstract

Purpose: Rare diseases substantially contribute to population morbidity and mortality. Understanding rare disease health-related quality of life (HRQL) is essential for evaluating platform-based interventions that aim to tackle multiple rare diseases at a time. However, most HRQL studies focus on single or select group of rare diseases, often in a single country. Our study aimed to identify patient- and disease-specific correlates of HRQL across diverse rare diseases. Methods: We conducted an international online survey of rare disease patients and caregiver proxies affected by a systematically identified sample of rare diseases. We calculated EQ-5D scores and conducted multivariate linear regression to examine sociodemographic and disease predictors of EQ-5D-5L visual analog scale (VAS) and utility scores (United States only). Results: A total of 1053 individuals affected by 103 different rare diseases participated, including 660 patients and 393 caregiver proxies. Disability status and disease prevalence correlated with poorer HRQL across models ( Conclusion: Our results suggest that across rare diseases, lower HRQL is associated with a reduced rare disease prevalence and disability status, among other predictors. Understanding the key correlates of HRQL is essential for developing interventions for improving health care delivery and quality of life for rare disease patients and families.

Indexed as

EQ-5DGenetic diseasesHealth related quality of lifeRare diseasesUtility score

Identifiers

PMID39669621
PMCPMC11613748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.